Formats
  1. Journal Article (67233)
  2. Meeting Abstract (33961)
  3. Book Section (5131)
  4. Review (3830)
  5. Editorial (2227)
  6. Conference Paper (1529)
  7. Guidelines (677)
  8. Correspondence (676)
  9. Research Letter (559)
  10. Book Whole (346)
  11. Miscellaneous (344)
Groups
  1. Department of Medicine (39413)
  2. GSK Faculty (22611)
  3. Solid Tumor Oncology Division (22232)
  4. Surgery (21386)
  5. Survivorship Research (15882)
  6. Sloan Kettering Institute Faculty (15701)

More Groups

People
  1. Marc Ladanyi (1332)
  2. Robert Motzer (1247)
  3. Victor Reuter (1229)
  4. Howard Scher (1130)
  5. Sergio Giralt (1065)
  6. Murray Brennan (1059)

More People

Years
  1. 2026 (7)
  2. 2025 (2818)
  3. 2024 (5600)
  4. 2023 (5809)
  5. 2022 (6169)
  6. 2021 (5720)

More Years

Publications
  1. Journal of Clinical Oncology (8683)
  2. Blood (5169)
  3. Cancer Research (2703)
  4. International Journal of Radiation Oncology, Biology, Physics (2619)
  5. Laboratory Investigation (1890)
  6. Modern Pathology (1817)

More Publications

Publishers
  1. Elsevier Inc. (13939)
  2. American Society of Clinical Oncology (9275)
  3. Springer (7224)
  4. Nature Publishing Group (6435)
  5. American Association for Cancer Research (6026)
  6. American Society of Hematology (5550)

More Publishers

Results (116513)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)
    Meeting Abstract

    Makker, V.; Taylor, M. H.; Aghajanian, C.; Oaknin, A.; Mier, J.; Cohn, A. L.; Romeo Marin, M.; Bratos Lorenzo, R.; Brose, M. S.; DiSimone, C.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial
    Meeting Abstract

    Oaknin, A.; Moore, K.; Colombo, N.; Scambia, G.; Kim, B. G.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Tran, B.; Kouros-Mehr, H.; Fermin, A.; Horvath, L.; Roncolato, F.; Rettig, M.; Dorff, T.; Tagawa, S. T.; Subudhi, S. K.; Antonarakis, E. S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma
    Meeting Abstract

    Hoimes, C. J.; Rosenberg, J. E.; Srinivas, S.; Petrylak, D. P.; Milowsky, M.; Merchan, J. R.; Bilen, M. A.; Gupta, S.; Carret, A. S.; Yuan, N.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Redefining the IGCCCG classification in advanced non-seminoma
    Meeting Abstract

    Gillessen, S.; Collette, L.; Daugaard, G.; de Wit, R.; Tryakin, A.; Albany, C.; Stahl, O.; Fizazi, K.; Gietema, J. A.; De Giorgi, U. F. F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)
    Meeting Abstract

    Choueiri, T. K.; Larkin, J. M. G.; Pal, S. K.; Motzer, R. J.; Venugopal, B.; Alekseev, B. Y.; Miyake, H.; Gravis, G.; Bilen, M. A.; Chudnovsky, A.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC)
    Meeting Abstract

    Van Cutsem, E.; Golan, T.; Hammel, P.; Reni, M.; Macarulla, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients
    Meeting Abstract

    Awada, A. H.; Harding, J. J.; Kotecki, N.; Aftimos, P. G.; Decaens, T.; Dreyer, C.; Ansaldi, C.; Rachid, M.; Serdjebi, C.; Halfon, P.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the CELESTIAL study
    Meeting Abstract

    Freemantle, N.; Abou-Alfa, G. K.; Cheng, A. L.; Kelley, R. K.; Valcheva, V.; Benzaghou, F.; Mollon, P.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • GLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2(+)/HER2(-) locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Meeting Abstract

    Shah, M.; Ajani, J. A.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D. V.; Enzinger, P.; Ilson, D.; Kim, S.; Lordick, F.; Shitara, K.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save